The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study

BACKGROUND: PD-1/L1 inhibitor-based immunotherapy is currently under investigation in biliary tract cancer (BTC). Apatinib combined with camrelizumab has achieved promising results in various tumor types. The aim of this study was to assess the safety and efficacy of apatinib plus camrelizumab for a...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Front Oncol
Main Authors: Wang, Dongxu, Yang, Xu, Long, Junyu, Lin, Jianzhen, Mao, Jinzhu, Xie, Fucun, Wang, Yunchao, Wang, Yanyu, Xun, Ziyu, Bai, Yi, Yang, Xiaobo, Guan, Mei, Pan, Jie, Seery, Samuel, Sang, Xinting, Zhao, Haitao
פורמט: Artigo
שפה:Inglês
יצא לאור: Frontiers Media S.A. 2021
נושאים:
Oncology
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC8071846/
https://ncbi.nlm.nih.gov/pubmed/33912461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.646979
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים